Sarah Pugh, United States of America

Pfizer, Inc Medical Affairs

Poster Author Of 1 e-Poster

Online Abstracts Population Sciences - Epidemiology, Economics, and Mathematical Modelling D1 Epidemiology, Economics, and Mathematical Modelling

Author Of 2 Presentations

COVERAGE OF THE 20-VALENT CONJUGATE VACCINE AGAINST INVASIVE PNEUMOCOCCAL DISEASE BY AGE GROUP IN THE UNITED STATES, 2017 (ID 237)

Abstract

Background

The United States experienced a substantial reduction in the incidence of invasive pneumococcal disease (IPD) following the introduction of pneumococcal conjugate vaccines (PCVs), PCV7 in 2000 and PCV13 in 2010, yet, disease remains. Expanded valency PCVs, PCV15 and PCV20 that contain two and seven additional serotypes compared to PCV13, are in advanced development.

Methods

We used the CDC Active Bacterial Core surveillance (ABCs) data from 2017 to quantify the incidence and to assess PCV coverage of IPD. ABC is an active laboratory and population-based surveillance system in 10 geographically diverse sites in the United States. Analyses were limited to the serotypes covered by PCV13 (1,3,4,5,6A,6B, 7F,9V,14,18C,19A,19F,23F, plus 6C, which is highly-related to 6A), PCV15 (PCV13-types, 22F,33F), and PCV20 (PCV15-types, 8,10A,11A,12F, plus 15C, which is highly-related to 15B).

Results

In 2017, non-PCV13 and PCV13 serotypes accounted for 63.1-75.0% and 25.0-36.9% of IPD cases across different age groups. The additional two serotypes in PCV15 and the seven serotypes in PCV20 accounted for 8.3-17.0% and 23.8-37.1% of the remaining IPD cases, respectively (Table).

isppd 2020_usbod_2020.0102 table.jpg

Conclusions

PCV20 could address a substantial remaining burden of IPD, covering an estimated 55.1-66.1% of cases across all age groups.

Hide